NextCure Inc., a clinical-stage biopharmaceutical company, has announced preclinical data demonstrating the effectiveness of NC605, a novel anti-Siglec-15 antibody, in treating osteogenesis imperfecta $(OI)$ in a well-established mouse model. The study results showed that NC605 improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. These findings were presented at the Brittle Bone Society Meeting on July 24, 2025. Currently, there is no FDA-approved standard of care for OI, and NC605 could offer significant therapeutic benefits for patients suffering from this rare disorder, characterized by high bone turnover and fragility. NextCure is actively seeking financial partners to advance NC605 towards an Investigational New Drug submission within 12 to 18 months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.